1
Views
0
CrossRef citations to date
0
Altmetric
Research Article

BROADSHEET NUMBER 51: HLA AND DISEASE ASSOCIATIONS

Pages 202-212 | Published online: 06 Jul 2009

  • Garboczi DN, Ghosh P, Utz U, et al. Structure of the complex between human T cell receptor, viral peptide, and HLA-A2. Nature 1996; 384: 134-41.
  • Rammensee HG; Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41: 178-228.
  • Kropshofer H, Hammerling GJ, Vogt A. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 1997; 18: 77-82.
  • Bodmer JG, Marsh SGE, Albert ED, et al. Nomenclature for factors of the HLA system, 1996. Hum Immunol 1997; 53: 98-128.
  • Elliott T. How does TAP associate with MHC class I molecules? Immunol Today 1997; 18: 375-9.
  • Maffei A, Papadopoulos K, Harris PE. MHC class I antigen processing pathways. Hum Immunol 1997; 54: 91-103.
  • Koopman JO, Hammerling GJ, Momburg F. Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Curr Opin Immunol 1997; 9: 80-8.
  • Pieters J. MHC class II restricted antigen presentation. Curr Opin Immunol 1997; 9: 89-96.
  • Amiel JL. Study of the Leukocyte Phenotypes in Hodgkin's Disease. Histocompatibility Testing. Copenhagen: Munksgaard, 1967.
  • Brewerton DA, Caffrey M, Hart FD, et al. Ankylosing spondylitis and HL-A27. Lancet 1973; i: 904-7.
  • Schlosstein L, Terasaki PT, Bluestone R, Pearson GM. High association of HL-A antigen, W27, with ankylosing spondylitis. New Engl J Med 1973; 288: 704-5.
  • Tiwari JL, Terasaki PI. HLA and Disease Associations. New York: Springer Verlag, 1985.
  • Davies JL, Kawaguchi Y, Bennett ST, et al. A genome wide search for human type 1 diabetes susceptibility genes. Nature 1994; 371: 130-7.
  • Brown MA, Pile KD, Kennedy LG, et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum 1998; 41: 588-95.
  • Greenberg A. Linkage analysis of "necessary" disease loci versus "susceptibility" loci. Am J Hum Genet 1993; 52: 135-43.
  • Rubin LA, Amos CI, Wade JA, et al. Investigating the genetic basis for ankylosing spondylitis: linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994; 37: 1212-20.
  • Isomaki H, Koota K, Martio J, et al. HL-A27 and arthritis. Ann Clin Res 1975; 7: 138-45.
  • Honen J, Hakala M, Reijonen H, Tilikainen A. B27 bearing HLA haplotypes in rheumatoid arthritis: characterization in Finnish patients. Hum Immunol 1991; 30: 7-10.
  • Gonzalez-Roces S, Alvarez MV, Gonzalez S, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997; 49: 116-23.
  • Lopez de Castro JA. The pathogenetic role of HLA-B27 in chronic arthritis. Curr Opin Immunol 1998; 10: 59-66.
  • D'Amato M, Fiorillo MT, Carcassi C, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995; 25: 3199-201.
  • Lopez-Larrea C, Sujirachato K, Mehra NK, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis: evidence for new associations. Tissue Antigens 1995; 45: 169-76.
  • Nasution AR, Mardjuadi A, Kunmartini S, et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 1997; 24: 1111-4.
  • Hill AV, Allsopp CE, Kwiatkowski D, et al. HLA-class I typing by PCR: HLA-B27 and an African subtype. Lancet 1991; 337: 640-2.
  • Brown M, Jepson A, Young A, et al. Spondyloarthritis in West Africa: evidence for a non-B27 protective effect. Ann Rheum Dis 1997; 56: 68-70.
  • Khan M, Braun JW, Jushner J, et al. HLA-B27 in ankylosing spondylitis: differences in frequency and relative risks in American blacks and Caucasians. J Rheumatol 1997; 4 (Suppl 3): 39-43.
  • MacLean L. HLA-B27 subtypes: implications for the spondyloarthropathies. Ann Rheum Dis 1992; 51: 929-31.
  • Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990; 11: 137-42.
  • Robinson WP, van der Linden SM, Khan MA, et al. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum 1989; 32: 1135-41.
  • Brown MA, Pile KD, Kennedy LG, et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996; 55: 268-70.
  • Wordsworth BP, Pile KD, Buckley JD, et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet 1992; 51: 585-91.
  • Dausset J. Iso-leuco-anticorps. Acta Haematol 1958; 20: 156-66.
  • Doherty PC, Zinkernagel RM. A biological role for the major histocompatibility antigens. Lancet 1975; i: 1406-9.
  • Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506-12.
  • Thorsby E. HLA-associated disease susceptibility. Which genes are primarily involved? Immunologist 1995; 3: 51.
  • Pile KD. Genetic factors in rheumatoid arthritis: HLA and candidate non-HLA loci. MD Thesis, University of Otago 1994.
  • Hall FC, Weeks DE, Camilleri JP, et al. Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis. Q J Med 1996; 89: 821-9.
  • Cough A, Faint J, Salmon M, et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994; 37: 1166-70.
  • O'Dell JR, Nepom BS, Haire C, et al. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 1998; 57: 209-13.
  • Dupont B, Oberfield SE, Smithwick EM, et al. Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet 1977; 2: 1309-12.
  • Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
  • Pietrangelo A, Camaschella C. Molecular genetics and control of iron metabolism in hemochromatosis. Haematologica 1998; 83: 456-61.
  • Powell LW, Bassett ML. Haemochromatosis: diagnosis and management after cloning of the HFE gene. Aust NZ J Med 1998; 28: 159-63.
  • Burney R, Pile K, Gibson K, et al. Analysis of the MHC class II encoded components of the HLA class I antigen processing pathway in ankylosing spondylitis. Ann Rheum Dis 1994; 53: 58-60.
  • Wordsworth BP, Pile KD, Gibson K, et al. Analysis of the MHC encoded transporters TAP1 and TAP2 in rheumatoid arthritis: linkage with DR4 accounts for the association with a minor TAP2 allele. Tissue Antigens 1993; 42: 53-5.
  • Maksymowych WP, Tao S, Li Y, et al. Allelic variation at the TAP1 locus influences disease phenotype in HLA-B27 positive individuals with ankylosing spondylitis. Tissue Antigens 1995; 45: 328-32.
  • Maksymowych WP, Wessler A, Schmitt EM, et al. Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individuals. J Rheumatol 1994; 21: 665-9.
  • Soizic D, Caillat-Zucman S, Hammer J, et al. Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. J Immunol 1997; 159: 2350-7.
  • Brown M, Wordsworth P. Predisposing factors to spondyloarthropathies. Curr Opin Rheumatol 1997; 9: 308-14.
  • Simmons WA, Leong LY, Satumtira N, et al. Rat MHC-linked peptide transporter alteles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. J Immunol 1996; 156: 1661-7.
  • Khare SD, Luthra HS, David CS. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta-2-microglobulin: a model of human spondyloarthropathies. J Exp Med 1995; 182: 1153-8.
  • Baum H, Davies H, Peakman M. Molecular mimicry in the MHC: hidden clues to autoimmunity. Immunol Today 1997; 17: 64-70.
  • Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.
  • Scofield RH, Kurien B, Gross T, et al. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995; 345: 1542-4.
  • Garcia F, Marina A, Lopez de Castro JA. Lack of carboxy-terminal tyrosine distinguishes the B*2706 bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated to ankylosing spondylitis. Tissue Antigens 1997; 49: 215-21.
  • Tanigaki N, Fruci D, Vigneti E, et al. The peptide binding specificity of HLA-B27 subtypes. Immunogenetics 1994; 40: 192-8.
  • Madden DR, Gorga JC, Strominger JL, Wiley DC. The three dimensional structure of HLA-B27 at 2.1A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992; 70: 1035-48.
  • Barber DF, Obeso O, Carcia-Hoyo R, et al. T-cell receptor usage in alloreactivity against HLA-B*2703 reveals significant conservation of the antigenic structure of B*2705. Tissue Antigens 1996; 47: 478-84.
  • Fiorillo MT, Meadows L, D'Amato M, et al. Susceptibility to ankylosing spondylitis correlates with the C terminal residue of peptides presented by various HLA-B27 subtypes. Eur J Immunol 1997; 27: 368-73.
  • Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human ß2m: an animal model of HLA B27 associated with human disorders. Cell 1990; 63: 1099-12.
  • Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA B27/human beta 2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-53.
  • Taurog JD, Richardson JA, Croft JT, et al. The germ free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-64.
  • Thorsby E. Invited Anniversary Review: HLA associated diseases. Hum Immunol 1997; 53: 1-11.
  • Chicz RM, Urban RG, Gorga JC, et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178: 27-47.
  • Breban M, Fernandez-Sueiro JL, Richardson JA, et al. T cells but not thymic exposure to HLA-B27 are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996; 156: 794-803.
  • Parham P. Presentation of HLA class I derived peptides: potential involvement in allorecognition and HLA-B27 associated arthritis. Immunol Rev 1996; 154: 137-54.
  • Khare SD, Bull MJ, Hanson J, et al. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role of B27 heavy chains and not B27 derived peptides. J Immunol 1998; 160: 101-6.
  • Marker-Hermann E, Meyer zum Buschenfelde KH, Wildner G. HLA-B27 derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis. Arthritis Rheum 1997; 40: 2047-54.
  • Gao XM, Wordsworth P, McMichael AJ, et al. Homocysteine modification of HLA antigens and its immunological consequences. Eur J Immunol 1996; 26: 1443-50.
  • McLean L, Hammer RE, Taurog JD. Cytokine profiles and site directed B27 mutation in the HLA-B27 transgenic rat. Hum Immunol 1996; 47: 74.
  • Wilcken DEL. Homocysteine and vascular disease. Med J Aust 1998; 168: 431-2.
  • Wuorela M, Jalkanen S, Kirveskari J, et al. Yersinia enterocolitica serotype 0:3 a hers the expression of serologic HLA-B27 epitopes on human monocytes. Infect Immun 1997; 65: 2060-6.
  • Kapasi K, Inman RD. HLA-B27 expression modulates Gram negative bacterial invasion into transfected L cells. J Immunol 1992; 148: 3554-9.
  • Laitio P, Virtala M, Salmi M, et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocyte cells. Eur J Immunol 1997; 27: 1331-8.
  • Warner TF, Madsen J, Starling J, et al. Human HLA-B27 gene enhances susceptibility of rats to oral infection by Listeria monocytogenes. Am J Pathol 1996; 149: 1737-43.
  • McGuire W, Hill AVS, Allsop CEM, et al. Variation in the TNF-a promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-12.
  • Verweij CL, Huizinga TWJ. Tumour necrosis factor alpha gene polymorphisms and rheumatic diseases. Br J Rheumatol 1998; 37: 923-6.
  • Petrovsky N, Harrison LC. HLA class II associated polymorphism of interferon-? production. Hum Immunol 1997; 53: 12-6.
  • Meyer CG, Gallin M, Erttman KD, et al. HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection. Proc Natt Acad Sci USA 1994; 91: 7515-9.
  • Brown JH, Jordetzky TS, Gorga JC, et al. Three dimensional structure of the human class II histocompatibilhy antigen HLA-DRI. Nature 1993; 364: 33-9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.